Economics of “Delinking” Are Still Not Good
Delinking would lead to higher costs for patients and taxpayers and put more money in the pockets of brand drug manufacturers.
Patent Thicket Remedies
Yesterday, the Initiative for Medicines, Access, and Knowledge I-MAK took an important step by proposing six policy solutions to address patent thickets that block generic and biosimilar drug competition.
The Economics of “Delinking” PBM Compensation
Pharmacy benefit managers (PBMs) are a popular Congressional target of late.
MGA Releases White Paper on Role of PBMs in US Drug Pricing Debate
MGA latest white paper, by CEO Alex Brill, looks at the role of pharmacy benefit managers (PBMs) in the US prescription drug market.
Unintended Consequences of Limiting PBMs
As Congress stumbles toward a government shutdown, health policy legislation continues to simmer in the background.
- Economics of “Delinking” Are Still Not Good
- The Child Tax Credit: Tradeoffs and Preferences
- Oregon’s Measure 118: The Turnover Tax Is the Worst
- Dueling Child Tax Credit Proposals: Harris vs. Vance
- Trump Proposes Bringing Back the Deduction for Auto Loan Interest
- Overtime Income Tax Break: Not Illogical, Just Costly and Complicated
- Presidential Candidates’ Dueling Child Credit Expansions Explained
- A Tip Exemption Is Not Sound Tax Policy
- Implications of Cannabis Legalization for the US Federal Budget
- Alex Brill Writes to FTC Regarding Interim Pharmacy Benefit Manager Report
